|
|
|
Early Phase Clinical Trials: Canada (Rolling applications) |
|
|
|
Dear Dr. Takacs-Cox,
I am reaching out to you on behalf of the Weston Brain Institute, which supports translational research to accelerate the development of therapeutics for neurodegenerative diseases of aging. We are pleased to launch the Early Phase Clinical Trials: Canada program.
Please kindly share this message with your colleagues and researchers. |
|
|
|
Program Overview |
The Early Phase Clinical Trials program was created to provide significant support for clinical trials and/or clinical trial sub-studies that have excellent preliminary data. |
|
|
|
|
Funding |
Up to $1,500,000 per project over up to 4 years |
|
|
|
|
Eligibility |
Principal applicants must be at or above the level of Assistant Professor or equivalent, and be affiliated with a Canada Revenue Agency-qualified donee institution located in Canada. Project must be a clinical trial and/or a clinical trial sub-study(s) that accelerates the development of therapeutics for neurodegenerative diseases of aging, and must involve the development of a therapeutic, and/or a tool. |
|
|
|
1. The Institute has updated which tools are in scope. Please read the What We Fund page on our website before applying to ensure your project is in scope. 2. The Early Phase Clinical Trials program will now be run on a rolling basis. |
|
|
|
For more information, please see the attached Request for Applications (RFA) or visit our website. Please feel free to contact me with any questions, including whether a potential idea is in scope. |
|
|
|
Thank you,
Cristina |
|
|
|
Cristina Tang, PhD | Senior Research Programs Specialist, Weston Brain Institute | 22 St. Clair Ave. E, Toronto, Canada, M4T 2S3 | +1 416-965-5356 | cristina.tang@weston.ca | www.westonbraininstitute.ca |
|
|
|
*if you would like to unsubscribe from our mailing list, please email neuro@weston.ca |
This email message is confidential, may be legally privileged and is intended for the exclusive use of the addressee. If you received this message in error or are not the intended recipient, you should destroy the email message and any attachments or copies, and you are prohibited from retaining, distributing, disclosing or using any information contained. Please inform us of the delivery error by return email. Thank you for your cooperation.
Le présent message électronique est confidentiel et peut être couvert par le secret professionnel. Il est à l’usage exclusif du destinataire. Si vous recevez ce message par erreur ou si vous n’en êtes pas le destinataire prévu, vous devez détruire le message et toute pièce jointe ou copie et vous êtes tenu de ne pas conserver, distribuer, divulguer ni utiliser tout renseignement qu’il contient. Veuillez nous informer de toute erreur d’envoi en répondant à ce message. Merci de votre collaboration.
UNSUBSCRIBE